The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Claudia Proto
Honoraria - AstraZeneca Canada; Bristol Myers Squibb Foundation; MSD; Roche
Consulting or Advisory Role - AstraZeneca Spain; MSD; Roche
Research Funding - AstraZeneca Japan; Bristol Myers Squibb Foundation; Celgene; Daiichi Sankyo; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca Canada; MSD; Roche
 
James M Dolezal
No Relationships to Disclose
 
Arsela Prelaj
No Relationships to Disclose
 
Luca Agnelli
No Relationships to Disclose
 
Tiziana Triulzi
No Relationships to Disclose
 
Alessandra Fabbri
No Relationships to Disclose
 
Roberto Ferrara
Consulting or Advisory Role - BeiGene; Merck Sharp & Dohme
 
Francesco Sgambelluri
No Relationships to Disclose
 
Tommaso Torelli
No Relationships to Disclose
 
Silvia Brich
No Relationships to Disclose
 
Sara Manglaviti
No Relationships to Disclose
 
Andrea Anichini
No Relationships to Disclose
 
Roberta Mortarini
No Relationships to Disclose
 
Giorgio Trinchieri
No Relationships to Disclose
 
Giancarlo Pruneri
Honoraria - Genomic Health; Novartis; Roche
Consulting or Advisory Role - ADS Biotec; ADS Biotec
Research Funding - Roche; Roche Molecular Diagnostics
 
Filippo G. De Braud
Honoraria - Amgen Astellas BioPharma; BMS; Incyte; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Incyte; Menarini; Nerviano Medical Sciences; Nerviano Medical Sciences; Novartis Italy; Roche; Sanofi
Research Funding - Basilea Pharmaceutical; Bayer Health; Bristol-Myers Squibb/Medarex; Daiichi Sankyo Europe GmbH; Exelixis; Ignyta; incyte; Janssen Oncology; Kymab (Inst); Loxo (Inst); MedImmune; Merck KGaA; Merck Serono (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Valter Torri
No Relationships to Disclose
 
Monica Ganzinelli
No Relationships to Disclose
 
Giuseppe Lo Russo
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; italfarmaco; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); GlaxoSmithKline (Inst); MSD Oncology; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD; Roche